Rest Ez Inc.

FRC's fair value estimate for Rest Ez Inc., and the rating behind it. RTEZ last traded at $70.00, 636.4× trailing earnings — the estimate is read against that market price. FRC analysts run the firm's valuation model across the companies on this platform to estimate what each one is worth, rather than republishing a consensus average. Shows the current estimate, our rating, and when it was last revised. A free account covers 7 company valuations a month; a paid subscription is unlimited.

Valuation, profitability, liquidity and leverage ratios for Rest Ez Inc.. Starting points for Rest Ez Inc.: P/E 636.4, beta 1.77 — an Medical - Pharmaceuticals name. P/E, P/B, EV/EBITDA, margins, return on equity, current ratio and debt coverage, each shown against the company's own history.

Dividend history, yield and payout sustainability for Rest Ez Inc.. Rest Ez Inc. does not currently pay a regular dividend, so this section tracks capacity rather than history. Per-share payments, yield over time, payout ratio and growth streak, with coverage measured against free cash flow.

Reported vs. expected earnings history for Rest Ez Inc.. EPS surprises by quarter, revenue against estimates, and the upcoming reporting date.

Income statement, balance sheet and cash flow history for Rest Ez Inc.. Rest Ez Inc. has reported as a listed company since 2025. Annual and quarterly filings with period-over-period comparison, so you can trace how revenue, margins and cash generation have moved.

Rest Ez Inc. valued side by side against its closest peers. Rest Ez Inc. is measured against Medical - Pharmaceuticals peers within the Healthcare sector. Peer-relative multiples and operating metrics, so the valuation is read in the context of its own sector rather than in isolation.

Which institutions hold Rest Ez Inc., and how their positions are changing. At a $1.93B market value, institutional positions materially move Rest Ez Inc.'s register. Top holders, position sizes, and quarter-over-quarter accumulation or distribution from regulatory filings. Included with FRC Premium.

Buying and selling by Rest Ez Inc. executives and directors. Shares of Rest Ez Inc. have traded between $1.00 and $70.00 over the past 52 weeks — context for the timing of the transactions below. Insider transactions as disclosed to regulators, with role, size and date — the clearest read on how the people running the company are positioned. Included with FRC Premium.

U.S. Senate disclosures naming Rest Ez Inc.. Rest Ez Inc. is a $1.93B Healthcare company. Senators' reported transactions in this security, alongside the fundamentals — a signal most research platforms leave out entirely. Included with FRC Premium.

U.S. House of Representatives disclosures naming Rest Ez Inc.. Representatives' reported transactions in this security, shown next to the company's fundamentals. Included with FRC Premium.

Latest headlines and company announcements for Rest Ez Inc.. Coverage tracks Rest Ez Inc. within Medical - Pharmaceuticals (Healthcare). Press releases and market coverage, newest first.